Physician profile
Eldon Severin Beard
NPI 1205896883
$5,996.11
in general payments reported to CMS, 2019-2025
31 companies · $16.37 in 2025
The $16.37 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $837 · 2020: $1,164 · 2021: $1,205 · 2022: $1,105 · 2023: $1,021 · 2024: $648 · 2025: $16.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,685.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,423.72 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $1,095.28 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $485.69 | 2019-2024 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $405.36 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.43 | 2019-2023 | Jardiance |
| Paratek Pharmaceuticals, INC. | $314.64 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $284.99 | 2019-2023 | Trulance, Xifaxan |
| Glaxosmithkline, LLC. | $283.03 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $258.84 | 2020-2024 | |
| Esperion Therapeutics, INC. | $177.25 | 2020-2023 | Nexletol |
| Abbvie INC. | $138.19 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $89.08 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $79.56 | 2021-2023 | |
| Genentech USA, INC. | $60.63 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $58.31 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $57.87 | 2021-2023 | Contrave, Onzetra Xsail |
| Janssen Pharmaceuticals, INC | $51.58 | 2019-2021 | |
| Amgen INC. | $47.02 | 2020-2023 | Otezla, Repatha |
| Exact Sciences Corporation | $46.63 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $45.11 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.89 | 2023-2024 | Caplyta |
| Abiomed | $31.12 | 2024 | Impella |
| Medtronic, INC. | $30.14 | 2022 | |
| Mylan Specialty L.P. | $29.63 | 2020 | |
| Dexcom, INC. | $26.66 | 2023 | Dexcom G6 Transmitter |
| Eisai INC. | $23.42 | 2021 | |
| Vanda Pharmaceuticals INC. | $22.29 | 2024 | Hetlioz, Fanapt |
| Idorsia Pharmaceuticals US INC | $21.90 | 2023 | Quviviq |
| Aytu Biopharma, INC. | $18.23 | 2020 | |
| Vertical Pharmaceuticals, LLC | $17.21 | 2019 | |
| Astellas Pharma US INC | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eldon Beard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.